Jeffrey is a Partner at Averin in the San Francisco Bay Area, where he invests at the intersection of life sciences, healthcare, and technology—partnering with teams advancing therapeutics, care delivery, and the software infrastructure powering the future of healthcare and life sciences. He is driven by a belief that transformative technologies, when paired with exceptional teams, can meaningfully improve human health at scale.

Before joining Averin, Jeffrey led the life sciences and healthcare technology strategy at Novo Holdings, working with companies including Exscientia — where, as part of the company’s first institutional financing, he helped the founder reimagine the company’s strategy and executive team, and subsequently guided it through a $225m crossover round and $510m Nasdaq IPO, one of the largest listings by a European biotech — alongside Tempus (TEM) and Verana Health. Prior to Novo Holdings, Jeffrey was a Partner at Andreessen Horowitz (a16z) where he joined during the formation of their inaugural Bio Fund. At a16z, Jeffrey invested in and supported a broad portfolio across therapeutics, AI drug discovery, life sciences technology, digital health, and deep tech, including companies such as Devoted Health, Erasca (ERAS), Freenome, Insitro, and Omada Health.

Jeffrey earned an MD from Yale School of Medicine, an MBA from Harvard Business School, and an AB in Molecular and Cellular Biology from Harvard.